Recursion Pharmaceuticals, Inc. remains a Sell as pipeline progress, notably REC-4881 in FAP, fails to surpass cheap alternatives like Celebrex. REC-4881's Phase 1/2 data show a median polyp reduction ...
Troy Segal is an editor and writer. She has 20+ years of experience covering personal finance, wealth management, and business news. Michael Boyle is an experienced financial professional with more ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback